Clinical trials: Hypertrophic Cardiomyopathy (HCM), active
Hypertrophic Cardiomyopathy (HCM)
HCMR Re-Imaging Study
This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM).
- Trial name
- NCT07054073
- Testing
- None - observational study
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 314 people
- Sponsor
- Christopher Kramer
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
- Trial name
- FOREST-HCM (NCT04848506)
- Testing
- Aficamten (5 - 20 mg)
- Where
- 141 sites in United States, Argentina and 17 more
- Volunteers
- 900 people
- Sponsor
- Cytokinetics
Hypertrophic Cardiomyopathy (HCM)
COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
COLLIGO-HCM is a global observational study that will conduct observational research of hypertrophic cardiomyopathy (HCM) treatment in real-world clinical practice.
- Trial name
- COLLIGO-HCM (NCT06372457)
- Testing
- Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
- Where
- United States
- Volunteers
- 331 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy (HCM)
Aficamten and Patient-Reported Outcomes in Real-World nHCM
This multicenter, prospective, observational, real-world clinical study aims to evaluate the efficacy and safety of Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) by prospectively…
- Trial name
- CAMPHOR-HCM (NCT07846176)
- Testing
- receiving aficamten
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hypertrophic Cardiomyopathy (HCM)
Individualized Exercise Training in Hypertrophic Cardiomyopathy
Exercise intervention trials in patients with hypertrophic cardiomyopathy (HCM) have demonstrated an association with improvement in resting and exercise hemodynamics, ventricular remodeling, and anxiety/depression.
- Trial name
- GET-FIT HCM (NCT07835854)
- Testing
- Exercise Intervention, Physical Activity Handout
- Volunteers
- 60 people
- Sponsor
- Oregon Health and Science University
Hypertrophic Cardiomyopathy (HCM)
A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population
This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings.
- Trial name
- HCM (NCT06775665)
- Testing
- No interventions were applied to the patients.
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hypertrophic Cardiomyopathy (HCM)
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic…
- Trial name
- BRAVE-HCM (NCT07103655)
- Testing
- mavacamten, Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, diltiazem
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hypertrophic Cardiomyopathy (HCM), Atrial Fibrillation (AF)
Mechanisms of Atrial Pathoelectrophysiology in HCM
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM).
- Trial name
- MAP HCM (NCT07454135)
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
HCM - Hypertrophic Cardiomyopathy
Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients Using Hybrid Digital Twin Solutions
The goal of SMASH-HCM is to develop a digital twin or virtual model of the heart and vascular system with sympathetic nerve control that integrates multi-scale and multi-organ spatiotemporal biophysical data from a multitude of…
- Trial name
- SMASH-HCM (NCT07131371)
- Where
- Finland
- Volunteers
- 2,500 people
- Sponsor
- Tampere University
Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitors
Radiomics Analysis of CMR Imaging for Arrhythmic Risk Prediction in Hypertrophic Cardiomyopathy, With Longitudinal Risk Reassessment After Mavacamten Therapy in Obstructive Patients
Hypertrophic cardiomyopathy (HCM) is one of the leading causes of sudden cardiac death (SCD), particularly in young and middle-aged individuals.
- Trial name
- RADIOMICS-OHCM (NCT07695272)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Centro Cardiologico Monzino
Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM)
Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy
The goal of this clinical trial is designed to characterise the safety, tolerability, efficacy, and PK of Aom0304 across oHCM and nHCM populations and to inform dose selection for future Phase 3 development.
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Obstructive HCM (oHCM), Non-obstructive HCM (nHCM)
- Trial name
- NCT07675668
- Testing
- QG101-23-0 enteric coated capsule (60/120/240/360 mg BID), QG101-23-0 enteric coated capsule (120/240/360/480mg BID)
- Volunteers
- 56 people
- Sponsor
- Amckaus PTY LTD.
Hypertrophic Cardiomyopathy (HCM)
LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
Hypertrophic cardiomyopathy (HCM) is a common (> 1/500 in the general adult population) genetically transmitted disease impacting markedly patients' lives from the early ages to the latest.
- Trial name
- LA-HCM (NCT07202897)
- Testing
- Anticoagulant treatment Rivaroxaban, Best medical therapy
- Where
- 17 sites in France
- Volunteers
- 532 people
- Sponsor
- Rennes University Hospital
Hypertrophic Cardiomyopathy (HCM)
A Real-world HCM-cohort Trial
Hypertrophic cardiomyopathy (HCM) is a genetically mediated myocardial disease predominantly caused by pathogenic mutations in sarcomeric protein genes and characterized by asymmetric left ventricular hypertrophy.
- Trial name
- NCT07638033
- Testing
- Standard of care
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Xijing Hospital
Hypertrophic Cardiomyopathy (HCM)
Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive…
- Trial name
- CMI-SWITCH (NCT07600177)
- Testing
- Aficamten
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oregon Health and Science University
Hypertrophic Cardiomyopathy (HCM)
Multicentre Hypertrophic Cardiomyopathy Registry
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition, affecting approximately 1 in 500 people. It causes the heart muscle to thicken, which can lead to blockages in blood flow (left ventricular outflow…
- Trial name
- NCT07381894
- Where
- United Kingdom
- Volunteers
- 2,500 people
- Sponsor
- University of Manchester
Hypertrophic Cardiomyopathy (HCM)
Perfusion Abnormalities in Hypertrophic Cardiomyopathy
The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.
- Trial name
- NCT06599229
- Testing
- myocardial contrast echo
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Virginia
Tumor, Cardiovascular Diseases
Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases
The purpose of this study is to conduct clinical research on [68Ga] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.
- Conditions
- Tumor, Cardiovascular Diseases, Pulmonary Fibrosis, Rheumatic Immune Diseases Involving Large Blood Vessels
- Trial name
- NCT07464132
- Testing
- Injection of 68Ga-NI-FAPI
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Hypertrophic Cardiomyopathy (HCM), Heart Failure
Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)
RASopathy-associated hypertrophic cardiomyopathy (RAS-CM) is a disease with high morbidity and high mortality if presenting during infancy.
- Conditions
- Hypertrophic Cardiomyopathy (HCM), Heart Failure, RASopathy
- Trial name
- RAS-CM (NCT07344480)
- Testing
- Retrospective data collection
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Hypertrophic Cardiomyopathy (HCM)
Precision Pharmacogenetics and Genotype Class Based Prediction of Mavacamten Response in Obstructive Hypertrophic Cardiomyopathy
This research study, aims to understand why a specific heart medication called mavacamten works better for some people with hypertrophic cardiomyopathy (HCM) than for others. We believe the answer might be in our genes.
- Trial name
- PRO-Gene Mava (NCT07408427)
- Testing
- Observational study, no new intervention offered
- Where
- United Kingdom
- Volunteers
- 140 people
- Sponsor
- University of Manchester
HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
This observational study aims to evaluate myocardial perfusion abnormalities using quantitative and qualitative cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) phenotypes…
- Conditions
- HCM - Hypertrophic Cardiomyopathy, Anderson Fabry Disease, Cardiac Magnetic Resonance Imaging, Amyloid Cardiomyopathy
- Trial name
- MyoPerf-HCM (NCT07382128)
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna